Navigation Links
Waging War on Wrinkles: Infini Cosmetic Associates Now Offers Recent FDA Approved Dysport - The Botox Alternative
Date:7/19/2009

Infini Cosmetic Associates in Scottsdale will carry Dysport™ the newly FDA approved wrinkle remover and rival to Botox®. Founder and Chief Surgeon, Dr. William Hall has performed thousands of injections over the last six years and trained many other professionals on Botox® and other injectable dermal fillers. Dr. Hall is very skilled in many of the advanced uses of Botox for: hyperhidrosis (excessive sweating) and nervous tics in the face, neck bands and wrinkles, chin creases and dimpling, lip lines, and lower facial shaping.

Scottsdale, AZ (PRWEB) July 19, 2009 -- Dr. William Hall, Founder and Chief Surgeon at Infini Cosmetic Associates in Scottsdale, announced that Infini Cosmetic Associates will carry Dysport™ the newly FDA approved wrinkle remover and rival to Botox®. Dr. Hall has performed thousands of injections over the last six years and trained many other professionals on Botox® and other injectable dermal fillers. Dr. Hall is very skilled in many of the advanced uses of Botox for: hyperhidrosis (excessive sweating) and nervous tics in the face, neck bands and wrinkles, chin creases and dimpling, lip lines, and lower facial shaping.

The arrival of Dysport™ into the U.S. aesthetics marketplace will no doubt increase competition between the two wrinkle treatments and multiply physician choices and cosmetic options within the same medical practice.

"This is a burgeoning industry and dermal fillers are very popular, so as doctors we are always being introduced to new products that compete with ones we already use - for example I use both Restylane® and Juvederm®," Hall stated. "I have used and trained with Botox® for years and patients love the results, I will offer Dysport™ too, but ultimately, the patients decide after they try both products and see the lasting results," Dr. Hall concluded.

Medicis, a dermal filler leader (known for their popular Restylane® and Perlane® facial fillers) will promote the Dysport™ brand as part of a U.S. sales agreement with the manufacturer, Ipsen. The addition of Dysport™ to their dermal filler arsenal positions Medic as a threatening opponent to the Allergan empire and their line of beauty treatments (Botox® and the Juvederm® - hyaluronic acid gel fillers).

BOTOX® Cosmetic is the solution for many wrinkles, which are actually creases that have been worn into the skin by making the same expression thousands of times. Hall explains - "expression lines" are often called frown lines, crow's feet, or forehead lines and appear due to the contraction of a muscle under the skin in that area. BOTOX® Cosmetic offers a much safer, less invasive option than cutting the muscle and provides more predictable and enhanced results. Some have called this unique therapy "a facelift in a bottle." Now, with Dysport™ there are more products to wage war on age.

Botox and dermal fillers produce long-lasting, amazing results. Visit http://www.infiniskin.com/Wrinkles.html to find out more about wrinkle restoration. For more information about Infini Cosmetic Associates, visit www.infiniskin.com to see photo galleries and the amazing special offers on Botox and dermal fillers. To set up a free consultation, call 480-946-7100.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2655704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. StructuRad Launches MacroLive(TM) with INFINITT and RamSoft at RSNA 2007
2. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
3. Management Consultancy Announces Inaugural Infinitive Championship Series
4. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
5. Infinity Business Systems of Tampa Expands Into Sarasota / Bradenton
6. Thank You, Dunder Mifflin Infinity
7. Infinity Property and Casualty Corporation Declares Quarterly Dividend
8. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
9. ProStor InfiniVault-DICOM Storage System Debuts in Rorke Data Booth at RSNA
10. Shaklee Hits the Road With Its Infinite Possibilities Tour
11. Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
(Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
Breaking Medicine Technology: